melloxacan antibody/antigen (BSA/OVA/KLH conjugated hapten)

anti-melloxacan antibody and Carrier-coupled antigen/immunogen (hapten-carrier conjugates)

Target products collectionGo to Drugs of Abuse diagnostics products collection >>


Product information

Catalog No.DescriptionUS $ Price (per mg)
GMP-SMT-206-11. BSA-melloxacan
2. Anti-melloxacan mouse monoclonal antibody
$2709.00
GMP-SMT-206-21. OVA-melloxacan
2. Anti-melloxacan mouse monoclonal antibody
$2709.00
GMP-SMT-206-31. BSA-melloxacan
2. Anti-melloxacan human monoclonal antibody
$2709.00
GMP-SMT-206-41. OVA-melloxacan
2. Anti-melloxacan human monoclonal antibody
$2709.00
GMP-SMT-206-Ag-1BSA-melloxacan$756.00
GMP-SMT-206-Ag-2OVA-melloxacan$756.00
GMP-SMT-206-Ab-1Anti-melloxacan mouse monoclonal antibody$1953.00
GMP-SMT-206-Ab-2Anti-melloxacan human monoclonal antibody$1953.00

Size: 1mg | 10mg | 100mg



Product Description


BSA-melloxacan

Cat No.GMP-SMT-206-Ag-1
Bioactivity validationCompetitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;
Products descriptionCompetitive immunoassay-validated hapten-carrier conjugates BSA-melloxacan with anti-Hapten antibody. The hapten hapten-carrier conjugates BSA-melloxacan had been validated with our anti-Hapten antibody Anti-melloxacan mouse monoclonal antibody via competitive ELISA test.
ApplicationELISA tests and other immunoassays;
Lateral flow immunoassay (LFIA);
LTIA
Immunonephelometry
Time-resolved Fluorescence Immunoassay (TRFIA)
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


OVA-melloxacan

Cat No.GMP-SMT-206-Ag-2
Bioactivity validationCompetitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;
Products descriptionCompetitive immunoassay-validated hapten-carrier conjugates OVA-melloxacan with anti-Hapten antibody. The hapten hapten-carrier conjugates OVA-melloxacan had been validated with our anti-Hapten antibody Anti-melloxacan mouse monoclonal antibody via competitive ELISA test.
ApplicationELISA tests and other immunoassays;
Lateral flow immunoassay (LFIA);
LTIA
Immunonephelometry
Time-resolved Fluorescence Immunoassay (TRFIA)
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Anti-melloxacan mouse monoclonal antibody

Cat No.GMP-SMT-206-Ab-1
Host of AntibodyMouse IgG
Bioactivity validationCompetitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;
Lateral flow immunoassay (LFIA);
ELISA IC50 (ppb)1.00
Products descriptionThe anti-Hapten antibody against hapten melloxacan had been validated with our hapten hapten-carrier conjugates BSA-melloxacan via competitive ELISA test.
ApplicationELISA tests and other immunoassays;
Lateral flow immunoassay (LFIA);
LTIA
Immunonephelometry
Time-resolved Fluorescence Immunoassay (TRFIA)
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Anti-melloxacan human monoclonal antibody

Cat No.GMP-SMT-206-Ab-2
Host of AntibodyHuman IgG1
Bioactivity validationCompetitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;
Lateral flow immunoassay (LFIA);
ELISA IC50 (ppb)1.00
Products descriptionThe anti-Hapten antibody against hapten melloxacan had been validated with our hapten hapten-carrier conjugates BSA-melloxacan via competitive ELISA test.
ApplicationELISA tests and other immunoassays;
Lateral flow immunoassay (LFIA);
LTIA
Immunonephelometry
Time-resolved Fluorescence Immunoassay (TRFIA)
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Biomarker Information


    1. Melloxacan - An Overview:

    Melloxacan, a non-steroidal anti-inflammatory drug (NSAID), plays a pivotal role in the landscape of in vitro diagnosis (IVD) due to its unique properties and applications. It is a synthetic compound characterized by its potent anti-inflammatory properties, rendering it an essential component in various diagnostic assays and tests.

    1.1 Role in IVD:

    Melloxacan assumes a distinctive role in IVD by acting as a competitive antigen, primarily in the form of a hapten-carrier conjugate. This conjugate is typically formed by covalently binding melloxacan to carrier proteins such as Bovine Serum Albumin (BSA) or Ovalbumin (OVA). This conjugation strategy enhances the antigen's immunogenicity, making it a preferred choice for antibody production.

    In the context of IVD, melloxacan serves as a critical component in assays designed to detect and quantify inflammation-related biomarkers or conditions. The rationale behind its use lies in the ability to generate highly specific antibodies against melloxacan, which, in turn, enable the precise detection of melloxacan in patient samples, most commonly blood or urine.

    1.2 Diagnostic Significance:

    Melloxacan's diagnostic significance cannot be overstated. Elevated levels of melloxacan in patient samples often serve as a biomarker for inflammation, making it an invaluable tool for diagnosing and monitoring various inflammatory diseases and conditions. This includes but is not limited to the assessment of arthritis, autoimmune disorders, and post-operative monitoring.

    The competitive antigen nature of melloxacan in diagnostic assays ensures that the produced antibodies are highly selective for this compound. This specificity is crucial in minimizing false-positive results and enhancing the accuracy of IVD tests, ultimately benefiting patient care and clinical decision-making.

    2. The Importance of Measuring Melloxacan:

    Measuring melloxacan concentrations in clinical settings and research laboratories holds immense importance for several key reasons:

    2.1 Inflammatory Disease Diagnosis:

    Melloxacan quantification serves as a reliable diagnostic tool for identifying and monitoring inflammatory diseases. Inflammation is a hallmark of various health conditions, ranging from rheumatoid arthritis to gastrointestinal disorders. Early detection of inflammation is crucial for initiating timely interventions and treatment plans.

    By measuring melloxacan levels in patient samples, healthcare professionals gain valuable insights into the presence and severity of inflammation, aiding in disease diagnosis and progression monitoring. This contributes to improved patient outcomes and the ability to tailor treatment strategies to individual needs.

    2.2 Treatment Efficacy Assessment:

    For individuals undergoing anti-inflammatory drug therapy, the measurement of melloxacan levels is instrumental in assessing treatment effectiveness. Monitoring changes in melloxacan concentrations over time provides healthcare providers with a quantitative metric to evaluate the response to treatment.

    A reduction in melloxacan levels following anti-inflammatory therapy indicates a positive treatment response, offering reassurance to both patients and clinicians. Conversely, persistent high levels may signal treatment resistance or the need for alternative therapeutic approaches.

    2.3 Personalized Medicine:

    The concept of personalized medicine has gained prominence in healthcare, emphasizing tailored treatment approaches based on individual patient characteristics. Measuring melloxacan levels contributes to this paradigm by providing clinicians with valuable information about a patient's specific inflammatory status.

    Tailoring treatment plans to the patient's unique profile ensures that interventions are both effective and well-tolerated. This not only enhances therapeutic outcomes but also minimizes potential side effects, promoting a more patient-centric approach to healthcare.

    2.4 Research and Drug Development:

    Beyond clinical applications, melloxacan quantification plays a vital role in pharmaceutical research and drug development. As researchers strive to develop novel anti-inflammatory drugs with improved efficacy and safety profiles, melloxacan serves as a benchmark for evaluating their potential.

    In preclinical studies and clinical trials, measuring melloxacan levels allows investigators to assess the impact of new compounds on inflammation. This data is crucial for making informed decisions about drug candidates, optimizing dosing regimens, and ensuring patient safety during drug development.

    2.5 Future Directions:

    As the field of IVD and anti-inflammatory drug development continues to evolve, the measurement of melloxacan is likely to remain a cornerstone of diagnostics and research. Ongoing advancements in assay technologies and the development of more specific antibodies will further enhance the precision and reliability of melloxacan quantification.

    In conclusion, the meticulous measurement of melloxacan concentrations has far-reaching implications, encompassing the diagnosis and management of inflammatory conditions, treatment assessment, personalized medicine, and the advancement of anti-inflammatory drug research and development. Its versatility and specificity make it an indispensable tool for healthcare professionals and researchers alike, contributing to improved patient care and the continued progress of medical science.



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.